Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2004-11-30
2011-10-11
Stoica, Elly-Gerald (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C530S387100, C530S387900
Reexamination Certificate
active
08034340
ABSTRACT:
Methods and agents for immune modulation and methods for identifying putative immune modulators are provided.
REFERENCES:
patent: 5843721 (1998-12-01), Rothe et al.
patent: 6010853 (2000-01-01), Kanteti et al.
patent: 2003/0092044 (2003-05-01), Goddard et al.
patent: 03/087374 (2003-10-01), None
patent: 9737016 (1997-10-01), None
patent: 9854323 (1998-12-01), None
patent: 03087380 (2003-10-01), None
patent: 2005033142 (2005-04-01), None
McEachern et al. , BRCA1 splice variants exhibit overlapping and disctinct transcriptional transactivational activities. J Cell. Biochem., 89, 120-132, 2003.
Joske DJL,Chronic myeloid leukaemia: the evolution of gene-targeted therapy. Med. J. Aust., 189,277-282, 2008.
Richardson et al, Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene therapy, 5, 635-644, 1998.
Lo et al. Intracellular Antibodies (Intrabodies) and Their Therapeutic Potential. Handb. Exp Pharmacol. 181, 343-373, 2008;Y.Chernajovsky, A.Nissim (eds.) Therapeutic Antibodies, Springer-Verlag Berlin Heidelberg 2008.
Katayama et al. A possible role for the loss of CD27-CD70 interaction in myelomagenesis. Br J Haematol. 120, 223-234, 2003.
Wendtner et al. The Potential of Gene Transfer into Primary B-CLLCells Using Recombinant Virus Vectors. Leukemia & Lymphoma, 45, 897-904, 2008.
Lobato et al., Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol. Med. 9, 390-396, 2003.
Christman, J.W. et al, “Nuclear Factor kappa B: A Pivotal Role in the Systemic Inflammatory Response Syndrome and New Target for Therapy”, Intensive Care Med., 24:1131-1138 (1998).
Lin, X. et al., Molecular Determinants of NF-kappaB-Inducing Kinase Action, Molecular and Cellular Biology, 18(10):5899-5907 (1998).
Xiao, G. et al., “NF-kappaB-Inducing Kinase Regulates the Processing of NF-kappaB2 p100”, Molecular Cell, 7:104-409 (2001).
Yin, L. et al., “Defective Lymphotoxin-beta Receptor-Induced NF-kappaB Transcriptional Activity in NIK-Deficient Mice”, Science, 291:2162-2165 (2001).
Kumar et al., “Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers : A possible role in duchenne muscular dystrophy”, 2003, Faseb J, 17:386-396.
PCT International Preliminary Report on Patentability, Jun. 7, 2006, in PCT/IL2004/001095.
Bodmer et al., The molecular architecture of the TNF superfamily, TRENDS in Biochemical Sciences, 27(1):19-26 (2002).
Ramakrishnan Parameswaran
Shmushkovich Taisia
Wallach David
Wang Wangxia
Browdy and Neimark PLLC
Stoica Elly-Gerald
Yeda Research and Development Ltd.
LandOfFree
Method for treating an immune disorder by decreasing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating an immune disorder by decreasing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating an immune disorder by decreasing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272853